Canada markets close in 3 hours 23 minutes

Innoviva, Inc. (INVA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.27-0.02 (-0.16%)
As of 12:36PM EDT. Market open.

Innoviva, Inc.

1350 Old Bayshore Highway
Suite 400
Burlingame, CA 94010
United States
650 238 9600
https://www.inva.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees112

Key Executives

NameTitlePayExercisedYear Born
Mr. Pavel Raifeld C.F.A.Chief Executive Officer754.67kN/A1984
Ms. Marianne Zhen CPAChief Accounting Officer & Secretary530.21kN/A1969
Mr. Stephen Basso M.B.A.Chief Financial OfficerN/AN/A1966
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Corporate Governance

Innoviva, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 6. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 4; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.